Biodegradable nanomats produced by electrospinning : expanding multifunctionality and potential for tissue engineering by Ashammakhi, N. et al.
R
E
V
IE
W
Copyright © 2006 American Scientific Publishers
All rights reserved
Printed in the United States of America
Journal of
Nanoscience and Nanotechnology
Vol. 6, 2693–2711, 2006
Biodegradable Nanomats Produced by
Electrospinning: Expanding Multifunctionality
and Potential for Tissue Engineering
N. Ashammakhi1!∗, A. Ndreu2, A. M. Piras3, L. Nikkola1, T. Sindelar4, H. Ylikauppila1, A. Harlin5,
M. E. Gomes, N. M. Neves, E. Chiellini3, F. Chiellini, V. Hasirci2, H. Redl4, and R. L. Reis
1Institute of Biomaterials, Tampere University of Technology, Tampere, Finland
2Biotechnology Research Unit, Department of Biological Sciences, Middle East Technical University, Ankara, Turkey
3Department of Chemistry and Industrial Chemistry, University of Pisa, Pisa, Italy
4Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria
5Institute of Fiber Materials Science, Tampere University of Technology, Tampere, Finland
With increasing interest in nanotechnology, development of nanofibers (n-fibers) by using the
technique of electrospinning is gaining new momentum. Among important potential applications of
n-fiber-based structures, scaffolds for tissue-engineering represent an advancing front. Nanoscaf-
folds (n-scaffolds) are closer to natural extracellular matrix (ECM) and its nanoscale fibrous struc-
ture. Although the technique of electrospinning is relatively old, various improvements have been
made in the last decades to explore the spinning of submicron fibers from biodegradable poly-
mers and to develop also multifunctional drug-releasing and bioactive scaffolds. Various factors can
affect the properties of resulting nanostructures that can be classified into three main categories,
namely: (1) Substrate related, (2) Apparatus related, and (3) Environment related factors. Devel-
oped n-scaffolds were tested for their cytocompatibility using different cell models and were seeded
with cells for to develop tissue engineering constructs. Most importantly, studies have looked at the
potential of using n-scaffolds for the development of blood vessels. There is a large area ahead
for further applications and development of the field. For instance, multifunctional scaffolds that
can be used as controlled delivery system do have a potential and have yet to be investigated for
engineering of various tissues. So far, in vivo data on n-scaffolds are scarce, but in future reports
are expected to emerge. With the convergence of the fields of nanotechnology, drug release and
tissue engineering, new solutions could be found for the current limitations of tissue engineering
scaffolds, which may enhance their functionality upon in vivo implantation. In this paper electrospin-
ning process, factors affecting it, used polymers, developed n-scaffolds and their characterization
are reviewed with focus on application in tissue engineering.
Keywords: Drug Release, Electrospinning, Multifunctional, Nanofiber, Nanotechnology, Regen-
eration, Scaffold, Tissue Engineering.
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1. INTRODUCTION
Nanotechnology is expanding through extensive research
after it has gained more attention, popularization and
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funds. An important target of nanotechnology is the
development of biomaterials that have improved physical,
chemical and biological properties.1 Developments in nan-
otechnology are dependent on parallel progress made in
processing methods.2!3!4!5 This will allow devices based
on nanomaterials to become more sophisticated and suc-
cessful. Major advances represent the development of
nanoparticles for various medical applications that involve
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diagnosis, treatment and assessment of prognosis.6
Another important advance is the exploitation of nano-
fiber (n-fiber) based materials in drug delivery and in tissue
engineering as biomimetic matrices. Such matrices should
be porous, fibrous and be capable of storage and delivery
of necessary signaling molecules. In our previous studies
on cartilage tissue engineering we have observed that bet-
ter cartilage formation was observed with thinner fibers
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(Unpublished data). Thus, we pursued approaches to
produce thin fibers for better chances of success in tissue
engineering. To produce fibers, phase separation,2!7!8
template synthesis,4 bi-component [islands-in-the-sea
(INS) structure] drawing,5 self-assembly,9 or electrospinn-
ing3!10–14 and combinations thereof15 can be used. Each of
these methods has its own advantages and disadvantages.
Phase separation can be used to produce nanoporous
foams, which are preferred in many areas. However, the
problem is that long time is needed to complete the
whole process. The same thing applies for self-assembly
process due to the need of thermodynamic equilibrium
in solution. Although, self-assembly can produce much
thinner n-fibers than those that can be produced by
e-spinning, self-assembly requires much more compli-
cated procedures and extremely elaborate techniques and
it is of low productivity.16 Solid or hollow fibers can be
obtained by means of template synthesis, but it does not
produce one-to-one continuous fibers. Drawing process
is limited by the fact that only viscoelastic materials
which can withstand applied stresses during the process
can be used. The problem can be overcome by multi-
component spinning of INS structures combined with
detachment of submicron fibers, with reasonable cost
but unfortunately this results in the formation of coarse
fibers (diameter larger than 500 nm) compared to other
methods. On the other hand, electrospinning (e-spinning)
is more economical, simpler, yields continuous fibers,
and is versatile enough to be applied to a variety of
materials. e-spinning is also the least expensive method
used to manufacture n-fibers.17 Furthermore, n-fibers can
be obtained with by using very small amounts of polymeric
solutions. e-spinning offers a simple and versatile method
for generating ultra-thin fibers from a wide range of mate-
rials that include polymers, composites and ceramics.18
e-spinning results in fibers with a diameter range
from 3 nm to several micrometers whereas the above-
mentioned other methods produce fibers with diameters
ranging from 500 nm up to a few micrometers and their
fibers are only a few micrometers long.14 Accordingly,
e-spinning is a suitable process for manufacturing n-fibers
for biomedical applications such as drug release19–29 or tis-
sue engineering.13!29–43
In e-spinning, resulting fiber diameter and alignment,
etc., can be controlled by manipulating processing para-
meters33 (See below). The principle of e-spinning is based
on exploiting the forces acting upon a solution droplet. An
electrically charged polymer solution forms at the tip of
syringe. On one side, surface tension tends to keep falling
droplets of the polymeric solution and on the opposite side,
electric forces act to pull the droplet. As the voltage applied
is increased, the droplet in the tip of the syringe elongates
more and more until the formation of a hyperbolic cone44
(also called Taylor cone after Taylor who has performed
fundamental investigations on the jet formation)45 occurs.
The e-spinning process has three stages:46
(a) initiation of the jet and the extension of the jet along
a straight path;
(b) the growth of a bending instability and further elonga-
tion or drawing of the jet that allows it to move in looping
and spiraling path;
(c) solidification of the jet into n-fibers.
2696 J. Nanosci. Nanotechnol. 6, 2693–2711, 2006
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In a typical e-spinning apparatus, the polymer solution
is contained in a syringe or a glass capillary. When an
electric field is applied to a polymer solution, ions in
the solutions aggregate at the surface of suspended liq-
uid/solution drop at the tip of the capillary, and the droplet
starts to act as an electrode.47 When the electric field
increases, the meniscus elongates to form a conical config-
uration (Taylor Cone), until at critical value of the electric
field, surface tension can no longer balance the hydrostatic
and electric forces and a thin jet is ejected form the surface
of the meniscus towards the nearest electrode of oppo-
site polarity, or electrical ground.48 After initiation, the jet
travels in straight line for typically about 0.02–0.03 m,
after which electrically driven instability is triggered by
the perturbations of the lateral position and lateral veloc-
ity of the jet, causing bending, winding, spiraling, and
looping path in three dimensions. The whipping jet was
observed by a high speed camera.49 Finally, the jet splits
into charged n-fibers that accumulate on collecting metal
screen (counter-electrode).50 During this period the solvent
evaporates and gives rise to the desired fibrous form. Due
to repulsive forces, produced n-fibers accumulate on the
collecting system in the form of three-dimensional (3D)
interconnected web.47 Most typical defect in fiber forma-
tion is the so called Rayleigh instability51 forming pearls
distributed along the fiber length. The greater the distance
the fiber needs to travel, the thinner it becomes. The dis-
tance that a fiber travels does influence how much of the
solvent evaporates. Under specific operation conditions,
which are not typical for the process, it is observed that
joining loops and fragmentation of fibers occurs leading
to the formation of irregular shapes of fibers.52 Applied
modeling of the process was developed in the recent
years53!54 but an engineering model that can enable pro-
cess control has not been established yet. The process
may occur either at room temperature or inside a fume
chamber depending on the used polymer and solvent type.
e-spinning without solvent is also possible by using melt
polymers in a vacuum chamber.55 However, the process
still needs more exploration and development to be of ben-
efit on commercial large scale production level. In the cur-
rent paper we review published reports on biodegradable
nanomats produced by e-spinning, both as plain and as
multifunctional bioactive and active molecule releasing
scaffolds with potential use in tissue engineering.
2. ELECTROSPINNING
2.1. Evolution and Principle
The development of the industrial technique of e-spinning
dates back to early in last century.56 Formalas was the first
to develop some patents on apparatus and process of how
filaments can be produced by means of electric fields.57–61
The term ‘electrospinning’ was introduced around 1994.
There was especially an increase in publications after 1998
Fig. 1. Schematic illustration of electrospinning set-up showing the
main three compartments of the e-spinning system: (A) syringe, (B) volt-
age supplier, and (C) collector.
of with the largest number being from USA.51 e-spinning
process has seen a great revival as nanotechnology became
popularized.
In e-spinning, a voltage supplier with a wide range of
tens of kilovolts, a glass syringe with a small needle and
a metal-made collector are the main three compartments
(Fig. 1). Typical conditions are in the range of 10–50 kV
potential difference typically from positive to ground, but
also from negative to positive with, e.g., regenerated cel-
luloses, with deposition distance of 100–350 mm. Poly-
mer solutions having viscosity of 100–3000 centipoises are
used. Productivity of one nozzle is typically 3–10 ml/h
of solution containing 2–25 wt% of polymer, markedly
depending on the molecular weight and type of polymer
and solvent system.
2.2. Factors Affecting e-Spinning
2.2.1. General
The science of electrically driven jets and electrically
charged particles was developed by pioneers over three
centuries. Bose developed an aerosol spray by applying
a high potential to a liquid in the end of glass capil-
lary already in 1745.62 Later, Lord Rayleigh studied the
instabilities that occur in electrically charged droplets con-
cluding the possibility of fiber drawing.63 Zeleney stud-
ied the role of surface instability in electrical discharges
from charged droplets and provided theoretical relations
for instability which were satisfied when the discharge of
the jet began.64 Vonnegut and Neubauer generated bound-
ary conditions for uniform streams of highly charged
droplets.65 Finally, Taylor analyzed the conditions at which
the point of a droplet deforms to conical shape, the Taylor
Cone, and showed how both conductivity and viscosity
play an important role in the process.66 The influence of
the experimental conditions on the morphology and stabil-
ity of the e-spun fibers were performed by Hayati67 and
Doshi.50 Factors that can influence e-spinning68!69 can be
summarized into three main categories:
(1) those related to substrate solution (polymer type and
concentration, solution dielectric constant, conductivity,
and surface tension),
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(2) apparatus related factors (flow rate of the solution,
hydrostatic pressure in the spinnerette, applied electric
field, and tip-collector distance), and
(3) environmental factors (temperature, humidity, air
velocity in the spinning chamber).
A correct setting of e-spinning parameters should allow
for producing average thin fibers with narrow variations in
diameter.
Modified technologies and apparatus were developed for
the production of advanced structures. For instance, scan-
ning tip electrodes orient formed n-fibers, but they can
be used also for increased uniformity especially on planar
nanocoatings.70 e-spinning can be performed on a rotating
electrode with multiple nozzle systems to form oriented
and 3D shaped constructions.71 Four cross located elec-
trodes can be used to produce a mesh.72 Finally, the pattern
of multiple electrodes can form any structure or pattern on
a flat substrate enable the development of even printing-
like results.
2.2.2. Substrate-Related Factors
When low molecular weight polymers are used, instead
of “electrospinning” it is “electrospraying” that occurs
when the onset of instability of process results in a spray
of small charged droplets.68!73 The ability to spin fibers,
blow films and perform other polymer processing oper-
ations on a material relies on the onset of entangle-
ments between chains. It usually occurs at a molecular
weight where a number of loops of the chain could possi-
bly occur, which is about 10,000 g/mole. Electrospraying
occurs, when entanglement of polymer chains does not
occur but still undergoes a bending instability that causes
a whip-like motion between the capillary tip and the
grounded target.74 All properties that can be related to the
entire chain, are affected by entanglements.75 Apart from
molecular weight and molecular weight distribution, other
thermodynamic properties, e.g., crystallization and glass
transition temperature have also effect on processing and
resulting n-fibers.76–78 The architecture of the polymer also
affects processing. In e-spinning, branched polymers seem
to need higher concentration than linear polymers to obtain
defect free n-fibers.79
Most of studies have revealed that increasing the con-
centration of polymer in the solution is accompanied with
an increase in fiber diameter and decrease in bead forma-
tion33!75!77!78!80–82!83 (Fig. 3). For example, poly(L-lactide)
[PLLA] fiber diameter was found to increase with increas-
ing polymer concentration, from 150–500 nm for 2% of
PLLA concentration to 800–3000 nm for 5% of PLLA.13
Regarding solvents, a highly volatile solvent is more
preferable but this may change according to the purpose
of processing. Chun et al.84 have investigated the effect
of two different solvents (isopropyl alcohol and dimethy-
lacetamide) on e-spinning of poly(ethylene-co-vinyl alco-
hol) [EVOH] and it was concluded that the presence of
hydrogen bondings can affect fiber diameter and
morphology.84 In our experiments,83 we have looked at two
different solvents (acetic acid and ethanol). Since ethanol
has a surface tension (22.4 dynes cm−1) lower than acetic
acid (28 dynes cm−1), easier evaporation of ethanol as
compared to acetic acid may have let to the formation
of thicker fibers. In another report, Fong et al.85 found
that high surface tension leads to the formation of beads
rather than fibers. In addition, ethanol has a dielectric con-
stant of 24.3 C2 m−2 N−1 at 25 #C, whereas acetic acid
has a constant of 6.2 C2 m−2 N−1 at 20 #C. Related to
this, Lee et al.77 indicated that the electrolytic tendency
of the solvent can be the most important parameter of
e-spinning process. Various n-fiber surface morphologies,
e.g., of e-spun PLLA n-fibers have been produced. A vari-
ety of size and orientation of nanopores have been pro-
duced in the range of 5.5–9.8 nm on the n-fibers by using
a variety and mixtures of solvents.78
It was observed that the addition of salt to polymer
solutions undergoing e-spinning results in the formation
of fibers thinner than those made from solutions contain-
ing no salt. This can be explained to occur as a result
of an increase in the charge density, which brings more
elongating forces acting on the polymeric solution and
therefore result in the formation of thinner and more
straight fibers.85 Choi et al.12 have demonstrated that con-
ductivity of poly(3-hydroxybutyrate-co-3-hydroxyvalerate)
(PHBV)-6 polymer can be improved by addition of some
salt like benzyl triethylammonium chloride (BTEAC).
We have also observed the effect of this salt on e-spun
PHBV-8 fiber morphology.82 PHBV-8 fiber structure that
was produced from solutions containing no salt had
resulted in bead formation and fibers were not straight.
When salt was added, bead formation was prevented and
more straight fibers were obtained82!86 (Fig. 2). In other
experiments83 the drug diclofenac was used in its sodium
salt form (DS). It was observed that with the addition
of DS to polymer dissolved in acetic acid, thinner fibers
were obtained. Similar observations were made when
Fig. 2. Electrospun nanomats made of PLGA 80/20 that was dissolved
in chloroform at a concentration of 5%. Average fiber diameter was 1 "m.
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(A)
(B)
Fig. 3. Effect of benzyl triethylammonium chloride (BTEAC) salt addi-
tion on fiber morphology (A) e-spun nanomats made from poly(hydroxy-
butyrate-co-3-hydroxyvalerate) copolymer having 8% hydroxyvalerate
(PHBV-8) solution that contained no salt; (B) e-spun nanomats made
from PHBV-8 solution that contained 2% BTEAC salt (Original magni-
fication ×1000). Note that when salt was used, nanofibers become more
straight and homogenous diameter with fewer strictures are obtained.
cefoxitin sodium23 was added to poly(lactide-co-glycolide)
(PLGA) polymer solutions, or when salts like NaH2PO4,
KH2PO4, and NaCl were added to poly(D/L-lactide)
(PDLLA) solutions.20 Lee et al. demonstrated that pro-
cessing polyvinyl chloride (PVC) dissolved in different
mixtures of tetrahydrofuran (THF) (dielectric constant 7.6
at 25 #C) and N,N-dimethylformamide (DMF) (dielectric
constant 36.7 at 25 #C), viscosity and surface tension of
the solution have changed. Thickest fibers were obtained
with THF and thinnest ones with DMF solvent.77
2.2.3. Apparatus-Related Factors
The flow rate of polymer solution is caused by the force
of applied electric field,87 gravity,56 and possible use of
pump.12 Zong et al.20 reported that lower volumetric feed
rates of solution that was delivered to the needle resulted
in slightly smaller fiber diameters due to faster solvent
evaporation.20 However, Megelski et al.78 demonstrated
that the formation of thicker e-spun polystyrene fibers with
higher flow rates was also possible. The size of the needle
has also an effect on fiber diameter. It was reported that
smaller needle orifice contributes to formation of smaller
fiber diameters.80
Applied voltage has been found to have crucial effects
on e-spinning.68!84!80 For example, the morphology of
e-spun PEO nanofibers changed from being straight,
defect-free fibers when spun at an initiating voltage of
5.5 kV, to fiber mats containing a high density of beads
when spun at an initiating voltage of 9.0 kV.68 Increase in
voltage is may decrease fiber diameter.80 However, above
certain level the increase of voltage does not have sig-
nificant effect on fiber diameter.80 A hypothesis for this
was presented and it implies that thinner n-fibers can be
obtained by using smaller needles due to smaller base of
Taylor cone and consequent thinner ejected jet.80 How-
ever, the difference was significant only between 16- and
20-gauge needles.80
Short distances between needle and collector can be
used when a highly volatile solvents is employed. Solvents
possessing low vapor pressure, e.g., water need longer dis-
tance for the evaporation of solvent. In addition, the dis-
tance between needle tip and collector has effect on fiber
morphology and diameter. Decrease in distance, regardless
of the concentration of polymer solution, results in the for-
mation of wet fibers and beaded structure.69!77 Moreover,
the shape of fibers changes from round to flat when the
distance is decreased.69
2.2.4. Environmental Factors
Environmental factors like temperature, humidity, and
air velocity in the e-spinning chamber have to be well
controlled to obtain similar fibers every time. Increase of
solution temperature has an effect on chain formation in
solution, decrease in the viscosity of solution, and increase
of solvent evaporation. All mentioned factors influence
fiber morphology. Demir et al.88 noticed that e-spinning
polyurethane at elevated temperature resulted in smaller
diameter distribution than fibers e-spun at room tempera-
ture. They noticed also that it was possible to e-spin solu-
tions having higher concentrations when the temperature
is elevated. On the other hand, Casper et al.89 e-spun
polystyrene fibers in atmosphere with greater than 30%
relative humidity and they observed micro- and nano-
structured pores in the surface of fibers. Optimizing the
conditions in order to get the best results is a challenging
task. Consequently, achieving reproducibility in this pro-
cess is a difficult task but not unachievable.
3. DEVELOPMENT OF BIODEGRADABLE
NANOMATS
3.1. General
Scaffolds for tissue engineering have to possess cer-
tain properties to enable successful engineering of tis-
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sue constructs in vitro and subsequent function upon
implantation in vivo. Thus, degradation rates of scaffolds
have to be tailored according to target application. Poros-
ity should be appropriately high to allow for homing and
population by cells in large numbers. Pores in the struc-
ture have to be interconnected in order to facilitate uniform
distribution of cells, the diffusion of necessary nutrients in
and waste products out.
Nanofibrous scaffolds can be prepared by methods like
e-spinning. Generally, nanomats are characterized by hav-
ing pores smaller than cells. They act rather as basement
membranes over which cells can spread. In other studies,
it was observed that cell appendages attach to n-fibers and
cell aggregate embrace fibers.39!41 It might be beneficial to
develop systems with large porosity to guide cell attach-
ment and allow cell population41 as well as easy diffusion
of nutrients and waste products.
Polymers that were investigated to develop biodegrad-
able nanomats include natural, synthetic, and blends of the
two14!82 (Table I). For tissue engineering, bioabsorbable
Table I. List of biodegradable and bioerodible polymers that were used
in e-spinning to produce n-fibers.
Polymer
A. Synthetic polymers
Poly(DL-lactide)10!20
Poly(L-lactide)10!13!20!33!36!38!90!91
Poly(#-caprolactone)26!32!43!90–95
Poly(lactide-co-glycolide) 10/90,36 65/35,98 75/25,23!36 or 85/1541
Poly(L-lactide-co-#-caprolactone) 75/25,99!130!132 70/30, 50/50, or 30/7091
Poly(DL-lactide-co-#-caprolactone) 5/9586
Poly(DL-lactide)-poly(ethylene glycol)-poly(DL-lactide) triblock
copolymer97
Poly(ethylene glycol)-poly(L-lactide) diblock copolymer10
Poly(ethylene glycol)-poly(DL-lactide) diblock copolymer10!36
Poly(ethylene oxide)145
Poly[bis(methylphenoxy)phosphazene]131
Poly(vinyl alcohol) coated Poly(p-xylylene)125
Poly(ethylene-co-vinyl alcohol)b84!133
Poly(#-caprolactone-co-ethyl ethylene phosphate)28!39
Poly(#-caprolactone-co-ethyl ethylene phosphate), surface grafted with
poly(acrylic acid)39
Poly(#-caprolactone) core coated with collagen shell (from calf skin)115
Poly(ester urethane)urea34
Buntan-1-olo hemister of poly(maleic anhydride–alt–2–methoxyethyl
vinyl ether polymer) (PAM14)P
Block polyesterurethane consisting of crystallizable blocks of
poly((R)-3-hydroxybutyric acid)-diol and blocks of
poly(#-caprolactone-co-glycolide)-diol linked with a diisocyanate
(DegraPol®)135
B. Natural-derived polymers
Silk fibroin29!103
Hyaluronic acid110
Cellulose146
Oxidised cellulose111
Hydroxypropylmethylcellulose24
Collagen type I (from calfskin93!101!147 or from human placenta101)
Collagen type II (from chicken sternae)102
Collagen type III (from human placenta)101
continued
Table I. Continued.
Polymer
Gelatin (denatured collagen from bovine skin)93
Solubilized alpha-elastin93
Tropoelastin (Recombinant human)93
Chitin148
Chitosan149
Polyhydroxybutarate valerate-882
Fibrin32!108
Fibrinogen108
C. Blends/Combinations
PLGA 10/90 and PLLA (75:25 wt%)36
PLGA 25/75 and PEG-PDLLA (85:15 wt%)36
PDLLA, PLGA 50/50, PDLA-b-PEG-b-PDLA and Lactide
(40:25:20:15 wt%)137
PLGA, PEG-b-PDLA diblock copolymer and PLA (80:15:5 wt%)23
PCL/PVA combination139
Silk fibroin and poly(ethylene oxide)104
Cellulose and heparin146
Starch and PCL (30:70 wt%)42!150
Poly(hydroxybutyrate-co-hydroxyvalerate) and P(L/DL)LA 70:30 (1:1)82
Poly(hydroxybutyrate-co-hydroxyvalerate) and PLLA (1:1)82
Poly(hydroxybutyrate-co-hydroxyvalerate) and PLGA 75:25 (1:1)82
Poly(hydroxybutyrate-co-hydroxyvalerate) and PLGA 50:50 (1:1)82
Collagen type I and III (both from human placenta) 50:50101
Collagen type I (from calf skin), elastin (from ligamentum nuchae), and
poly(D,L-lactide-co-glycolide) (45:40:15)35
Collagen (type I from calf skin), elastin (from bovine neck ligament) and
poly(ethylene oxide)134
Collagen-chondroitin sulfate (96:4 and 90:10)114
Collagen (type I from calf skin) and poly(ethylene oxide)134
Collagen (type I from calf skin) and poly(L-lactide-co-#-caprolactone)
70:30 (1:1 w/w)113
Collagen (type I from calf skin) and poly(#-caprolactone)31
Collagen (type I from calf skin) and poly(#-caprolactone)c115
Gelatin (type B, bovine skin) and polyanilinea151
Gelatin (type A, porcine skin) and poly(#-caprolactone)152
Elastin (from calf bovine neck ligament) and poly(ethylene oxide)134
aPolyalinine is not biodegradable.
bPartially biodegradable.
cCoaxial spinning.
polymers are preferred because they can be employed to
provide temporary scaffolding function for newly-forming
tissue and to be subsequently replaced by native tissue
with the polymer material getting removed by natural
and metabolic processes of the body. Hence, no resid-
ual material that can act as focus of irritation with possi-
ble infection, is left in the body. It is also important for
newly-formed tissues to take over by time and become
independent of the supporting scaffold. This is especially
important, e.g., in tissues like bone where physiological
loading is crucial.
There are certain polymers that have been used for
many years in surgery as implants, i.e., sutures, screws,
and plates, and they represent good candidates to use
as raw materials for producing nanomats for future use
in the clinic. Thus, studied polymers (Table I) included
PLLA,10!13!20!33!36!38!90!91 PLDLA,10!20 poly(#-capro-
lactone) (PCL),26!32!43!90–95 and their copolymers such as
PLGA23!36!41!92!96–98 and poly(#-capolactone-co-L-lactide)
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(PCL-PLLA),99 etc. These polymers have a well-
characterized behavior in the body and defined elimination
routes. Although e-spinning of natural polymers is more
challenging, there are various reports already on devel-
oping nanomats from natural polymers. Polymers of
natural origin that have been used to develop n-fibers,
include collagen,31!93!100–102 silk protein,103–105 elastin,106
tropoelastic93 elastin-mimetic peptide,107 fibrinogen,108!109
fibrin32!108 hyaluronic acid,110 oxidized cellulose,111 and
PHBV.82 Interesting enough, collagen type I n-fibers that
were produced using e-spinning exhibited the 67-nm
banding, which is seen in native collagen fibrils.101
In addition, smart polymers where bioerosion is depen-
dent on pH have also been studied by our group.83
Combinations of synthetic and naturally-derived polymers
were also used for combining properties of both. Studies
involved PCL coated with gelatin,112 PCL-PLLA coated
with collagen,30 blends of silk and PEO,29 blends of col-
lagen and PCL-PLLA,113 and blends of starch and PCL,42
etc. Our studies involved blends of PHBV with PDLLA,
PLLA, or PLGA.82 Blends of natural polymers were also
explored such as collagen and chondroitin sulphate.114
Mostly, nanomats produced by means of e-spinning
have a nonwoven structure. However, developing aligned
n-fibers has been one area of interest. For the production of
aligned n-fibers, instead of using a stationary collector, a
rotating collecting system is used.51 We have developed so
far aligned n-fibers by using a rotating cylinder.82 Aligned
fibers are important to guide regeneration of tissues like
neural,13 ligamentous,40 etc. Yang et al.,13 have demon-
strated that neural stem cells could attach and migrate well
and neurite outgrowth was supported by aligned n-fibers.
Human ligament fibroblasts were also found to be oriented
in the direction of aligned n-fibers,40 forming oriented bun-
dles and significantly more collagen than that produced by
cells cultured on randomly oriented fibers.
3.2. Developed Nanomats
So far, most of reports involved studies on develop-
ing plain n-scaffolds. However, recently, more functions
have been added to these scaffolds by combining drug
release properties to render such biomaterials multifunc-
tional. Characteristics of n-scaffolds can be controlled via
the functionalization of the n-fibers that can be achieved
through one of three main methods:115
(1) mixing bioactive agents with the biodegradable poly-
mer solutions to prepare bioactive composite n-fibers,
(2) surface modification of the whole nanofibrous scaf-
folds; or
(3) employing a coaxial e-spinning, to produce fibers with
core-shell structure.
This new category of bioactive multifunctional scaffolds
(Table II) has been developed after the convergence of
drug release and scaffold processing technologies. The
principle of local drug release has been developed to
avoid or at least limit side effects of drugs. In many
systems where implants are produced, heat-based pro-
cessing systems are used to manufacture drug releas-
ing implants,116–122 making the inclusion of heat-sensitive
molecules impossible. Employing e-spinning has enabled
researchers to develop multifunctional fibers and scaffolds
that are capable of releasing drugs,19–26!83!86!123!124
polypeptides,27–29!123–125 or polyneucleotiedes,96!97 etc. It
also allows for combining of more than one agent of differ-
ent categories in the multifunctional construct.123 In addi-
tion, one can extert control on the release of multiple
agents. This is especially important to enhance the multi-
functionality and take of tissue engineering “grafts” when
implanted in the body. Therefore, it is essential to develop
a system, that can deliver drugs/morphogens of interest
in the appropriate time, for appropriate duration and at
precise location. Depending on the characteristics that a
drug of interest has, there is a need for development of
drug special carriers since some drugs may have low sta-
bility, poor water solubility or high toxicity. Due to their
high surface area to volume ratio, and porosity, e-spun
n-fiber-based nanomats are interesting materials to be used
as multifunctional tissue engineering scaffolds.
During preparation of drug releasing nanomats, the drug
of interest is mixed with the appropriate polymer and
then the mixure is e-spun to obtain nanofibrous structures.
However, it is not clear from the results of some cases
whether added agent/drugs are included inside the fibers
or lie on their surface. This is affected by drug character-
istics. In contrary to other release systems, those produced
with e-spinning can be used to include both hydropho-
bic and hydrophilic drugs. A polymeric carrier leads to
the supression or delay of recrystallization of the drug
dispersed in it, by making the drug pharmaceutically use-
ful for the desired period of time.126 Verreck et al.126 have
demonstrated the possibility of delivering poorly water sol-
uble drugs in a controlled manner by using e-spun non-
biodegradable polymeric fibers. Itraconazole (antifungal
drug) and ketanserin (a selective S2-serotonin antagonist
for the acceleration of wound healing) were used as model
drugs.
Various strategies have been studied to control the
release kinetics of loaded agents from e-spun fibers. Drugs
can covalently be conjugated to the polymer matrix as
shown in some reports.25 Another method involves post-
electrospinning coating of drug-loaded n-fibers.125 A new
technique of coaxial e-spinning was also developed to pro-
duce fibers having a core and shell structure. The loaded
agent can be included in the core and shell would func-
tion as a control mechanism over the release of the loaded
agent.27 This method entails feeding of two different solu-
tions to be spun through two concentrically arranged nee-
dles. The co-electrospinning of the two solutions leads
to the formation of fibers having core and shell. The
method can be beneficial for containing and controlled
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Table II. Multifunctional/bioactive electrospun nanofiber-based nanomats.
Polymer Combined agent Ref.
A. Pharmaceutical agents
PLA (Medisorb® 100 L PLA), Poly(ethylene-co-vinyl acetate) and their
50:50 blend
Tetracycline hydrochloride [19]
Poly(DL-lactide), Poly(L-lactide) Mefoxin [20]
Poly(L-lactide) Rifampin, Paclitaxel [21]
Poly(lactide-co-glycolide) Cefoxin Sodium [22]
Poly(lactide-co-glycolide), poly(ethylene glycol)-b-poly(DL-lactide) Mefoxin® [23]
Hydroxypropylmethylcelluloseb Itraconazole [24]
Poly(lactide-co-glycolide), poly(ethylene glycol)-g-chitosan (composite
membrane)
Ibuprofen [25]
Poly(#-caprolactone) Heparin [26]
Poly(#-caprolactone) Dicolfenac sodium (Voltaren) [86]
Buntan-1-olo hemister of poly(maleic anhydride–alt–2–methoxyethyl
vinyl ether polymer) (PAM14)
Dicolfenac sodium (Voltaren) [83, 123, 124]
B. Polypeptides
Shell-core system: Poly(#-caprolactone) shell and poly(ethylene glycol)
core
BSA in the core [27]
Shell-core system: Poly(#-caprolactone) shell and poly(ethylene glycol)
core
Lysozyme in the core [27]
Buntan-1-olo hemister of poly(maleic anhydride–alt–2–methoxyethyl
vinyl ether polymer (PAM14)
Human serum albumin [123, 124]
Silk poly(ethylene oxide) Bone morphogenetic protein 2 (BMP-2) [29]
Poly(vinyl alcohol) coated with poly(p-xylylene) (PPX)a Fluorescin isothiocyanate labeled bovine serum albumin
(FITC-BSA)
[125]
Poly(vinyl alcohol) coated with poly(p-xylylene) (PPX)a Luceferase [125]
Poly(#-caprolactone-co-ethyl ethylene phosphate) Human $-Nerve growth factor (NGF) in bovine serum
albumin
[28]
C. Polynucleotides
Poly(lactide-co-glycolide), Poly(DL-lactide)-poly(ethylene glycol) pCMV$ plasmid encoding $-galactosidase [96]
Poly(lactide-co-glycolide), Poly(DL-lactide)-poly(ethylene glycol)-
poly(DL-lactide) (for DNA encapsulation)
pCMV$ plasmid encoding $-galactosidase [97]
D. Ceramics
Poly(#-caprolactone) CaCo3 [94, 136]
Polyhydroxybutarate valerate-5 Hydroxyapatite [129]
Poly(#-caprolactone) Hydroxyapatite [136]
Silk poly(ethylene oxide) Nano-Hydroxyapatite [29]
E. Ceramics and polypeptides
Silk poly(ethylene oxide) Nano-Hydroxyapatite /BMP-2 [29]
aPPX was used for coating and it is a highly hydrophobic and very solvent resistant polymer.
bTo assess the use of e-spinning for the difficult task of controlled delivery of a highly poorly water-soluble model drug. Water-soluble polymer, hydroxypropylmethylcellulose
(HPMC) was used.
release of water-soluble molecules such as proteins, with
potential use in tissue engineering. It has been empha-
sized that this process is easier and has a higher efficiency
than traditional methods used for encapsulation of growth
factors or proteins.27 Loscertales et al.127 reported on a
new method to generate steady coaxial jets with diameters
in the range of micro-/nano-meter size. This compound
jet was generated by the action of electro-hydrodynamic
forces resulting in the formation of an aerosol of monodis-
perse compound droplets with the inner liquid being sur-
rounded by the outer one. Resulting capsules had a diame-
ter of 0.15–10 "m. Co-electrospinning was thus employed
for the development of core-shell fibers to add more ver-
satility to the technique.128
Another study included bovine serum albumin or
luciferase release from e-spun PVA n-fibers that were
coated with hydrophobic poly(p-xylylene).125 Significant
retardation of release in the case of coated n-fibers was
observed, and the activity of the released enzyme was
maintained. This can offer a system that may be used
for tailoring drug release. In our studies, human albu-
min was used as a release control check.124 An approach
involving cross-linking of amino groups of incorporated
protein, in order to slow the release of loaded agents is
being explored by our groups in studies on multifunctional
scaffolds.124
Zeng et al.125 have found that the release of bovine
serum albumin (BSA) from poly(p-xylylene) (PPX)-
coated PVA/BSA composite can significantly be retarded
due to the PPX coating even at 37 #C. This has also been
found to be influenced by the thickness of the coating
layer. A further slower release of BSA was observed with
a PPX layer thickness of 250–300 nm as compared with
thickness of 80–100 nm. This effect is achieved due to the
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high hydrophobicity and solvent resistance properties of
PPX. Thus, control of release for prolonged time intervals
can be achieved by adapting water impermeability of the
shell polymer.
Changing voltage was also found to influence the rate
of release.24 For example, at 60 min, 40% release of the
antifungal Itraconazole release from samples processed
using 24 kV was seen while those processed using 16 kV
released 70% of the drug. Complete release was obtained
at <160 min for the 16 kV sample and at 240 min for
the 24 kV one. In this study, it was also demonstrated that
the use of e-spinning is useful for addressing the difficult
task of controlled delivery of a poorly water-soluble model
drug from a water-soluble polymer (hydroxypropylmethyl-
cellulose). e-spun samples were also found to result in a
slower dissolution in vitro as compared to powders made
of samples prepared by cast thin films or melt extrusion.
Zhong et al.114 have added chondroitin-6-sulfate (CS)
sodium salt (from bovine trachea) to type I collagen
(calf skin) and the blend was e-spun to n-scaffolds so
that in addition to mimicking native tissues structurally,
such biomimetic n-scaffolds may enhance biological inter-
actions with cells and speed up tissue regeneration by
introducing cell-specific ligands or extracellular signaling
molecules and by CS interaction with serum growth fac-
tors and cytokines.
3.3. Characterization of Nanomats
3.3.1. Material Properties
Important requirements of a scaffold are biocompatibility
and biodegradability so that no adverse tissue reactions
occur when implanted in tissues. Furthermore, it should
possess an appropriate surface chemistry and porosity to
allow easy attachment of cells and also good mechanical
properties to resist stresses that may occur. It is also impor-
tant to define morphology and structural characteristics
of the resulting scaffolds. Scanning electron microscopy
(SEM) and transmission electron microscopy (TEM) are
common tools that are used for the assessment of the struc-
ture of resulting nanomats and for various measurements,
such as fiber diameter, bead size (length and diameter),
fiber morphology, etc.69 Porosity can be measured using
porosimeter.41
Wide-angle X-ray diffraction (WAXD) is used for find-
ing out, e.g., orientation of polymer chains and crys-
tallization of polymer that can occur during e-spinning
process.69!20 With differential scanning calorimetry (DSC)
crystallization of n-fibers can also be studied. The molec-
ular structure of n-fibers manufactured from blends of the
two materials and their inter-molecular interactions can be
determined using NMR20 and Fourier transform infra-red
(FTIR).107
For mechanical properties of scaffolds, elongation-at-
break, ultimate strength and Young’s modulus are obt-
ained from the mechanical tests, which are increased
by increasing fiber diameter.77!81!102 Studies should also
include in vitro and in vivo evaluation of scaffolds behav-
ior and degradation.81!129
3.3.2. Drug Release Studies
When dealing with multifunctional nanomats, one has to
define drug or contained molecule release profiles. The
follow-up of drug release from nanomats takes place, usu-
ally, by studying specimens incubated in vitro. Appropriate
methods are used for the identification and calculation of
the amount of released agent. In studies on the release
of diclofenac sodium,83!86!124 we have employed UV-vis
spectroscopy where the absorbance of drug at 276 nm
was determined and the concentration of released drug is
calculated from its extinction coefficient at given wave-
length. For other molecules, appropriate methods such as
complex forming and immunoassays can be used. For
example, the release of human serum albumin can be
evaluated by a colorimetric assay. Sample and standard
absorbance at 562 nm can be measured by means of a
spectrophotometer.83
3.3.3. Cell Culture
Several cell culture studies were carried out to define cell-
compatibility studies, and much can be learnt from these
studies to enable the development of tissue engineering
constructs. These studies looked at the effect of scaffolds
on cell viability, proliferation, and differentiation. Studies
that aimed specifically at developing tissue engineering
constructs are increasingly being published. So far, various
types of cells have been used with n-fiber-based scaffolds
including endothelial cells (ECs),16!30!33!35!91!112!113!130–132
keratinocytes,103 hepatocytes,39 smooth muscle cells
(SMCs),31!34!35!99!101!130!132–134 myoblasts,135 satellite
cells,135 myofibroblasts,32 fibroblasts,41!103!115!133!136 lig-
ament fibroblasts,40 conjunctiva fibroblasts,114 articular
chondrocytes,102 osteoblast-like cells,42 calvarial derived
osteogenic cells,10 or osteoblasts,137 pre-osteoblastic
cells,96!97 osteoblasts,136!94 mesenchymal stem cells
(MSCs),29!41!43 neural stem cells,38 and cerebellum stem
cells.13 Most of cell-based studies involved plain polymers
except for very few studies that involved drug/active
molecule releasing nanoscaffolds. A study by Li et al.,29
investigated multifunctional bioactive silk fibroin fiber
scaffolds–based scaffolds, containing hydroxyapatite
nanoparticles (nHAp) and bone morphogenetic protein 2
(BMP-2), using human bone marrow-derived MSCs. In
another study, cell culture was used for the assessment
of released agent bioactivity. Chew et al.28 used PC12
cells (differentiate to a neuronal phenotype in presence
of human $-nerve growth factor NGF) to study the
bioactivity of NGF released from e-spun copolymer of
#-caprolactone and ethyl ethylene phosphate (PCLEEP).
Cells were found to differentiate into neurons indicating
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that released NGF has retained a degree of its bioac-
tivity. NGF release from the PCLEEP fibers extended
for up to 3 months, which is considered useful because
NGF has a short half-life in vivo (elimination half-life
of less than 5 h in adult rats138). In a study by Liang
et al.97 MC3T3-E1 (pre-osteoblastic cell line) were used
to evaluate the transfection efficiency of DNA delivered
from PLA-PEG-PLA triblock copolymer nanoparticles
incorporated in PLGA n-fibers. MC3T3 cells were incu-
bated with two types of DNA loaded scaffolds (those
that had block copolymer and those that had not). Those
scaffolds without the block copolymer were found to
contain degraded DNA (due to e-spinning), while DNA
released from scaffolds having the block copolymer was
structurally intact. Sustained release of intact DNA from
PLGA scaffold was measured. After seven days, a large
fraction (ca. 75%) of the DNA remained in the partially
degraded scaffold. There was no evident transfection in
cells incubated with PLGA and DNA scaffolds that had
no tribloc copolymer. Transfection was, on the other hand,
observed with scaffolds that had the triblock copolymer.
DNA complexed with the transfection reagent, Fugene,
resulted in further enhancement of transfection efficiency.
It was thought that control of the fabricated scaffold could
be developed to lead ultimately to improved transfection
efficiency.
Ito et al.129 studied PHBV n-fibrous film (fiber average
diameter of 185 nm) composited with HAp by soaking
in simulated body fluid. n-fibrous film was hydrophobic
when compared to PHBV cast (flat) film. After HAp depo-
sition, both of the surfaces were hydrophilic. They have
incubated COS-7 cells (originating from the kidney of
Africa green monkey) with developed materials for 1.5 h.
There was no explanation in the study as regards to why
these cells were specifically used. According to authors,129
these cells were used to study the interaction between the
n-fibrous film and cells. n-fibrous film was associated with
enhanced cell adhesion as compared with flat film. Cell
adhesion, however, was not significantly affected by HAp.
The number of adhered cells to the nanofibrous mats was
significantly higher than to flat surface films. HAp com-
position did not significantly affect cell adhesion.
Wutticharoenmongkol et al.136 used human osteosar-
coma osteoblast cell line (SaOS2) and mouse fibroblasts
(L929) in cytotoxicity tests to evaluate scaffolds that were
made of e-spun fibers of PCL, PCL containing CaCO3,
or PCL containing HAp nanoparticles. As-spun neat PCL
fibers had an average diameter of about 0.95 "m and
as-spun composite fibers had a diameter of 1.02–1.26 "m.
All of the three scaffold types were nontoxic to both types
of tested cells, suggesting that these materials can have a
potential for use as bone scaffolds.
Kim et al.137 have used immortalized mouse calvarial
osteoblasts (MC3T3-E1) to evaluate the cytotoxicity of
n-scaffolds that were made by e-spinning of multicompo-
nent PLA blends. Blends had PDLLA (40 wt%), PLGA
50/50 (25 wt%), poly(DL-lactide)-poly(ethylene glycol)-
poly(DL-lactide) [PDLLA-b-PEG-b-PDLLA] (20 wt%),
and lactide (15 wt%). Cells were incubated in media con-
taining either lactide or triblock copolymer at different
concentrations. It was found that at higher lactide con-
centrations (e.g., 30 mg/ml), cell viability decreased dra-
matically, especially by 2 and 3 days. On the other hand,
triblock copolymer did not affect cell proliferation even
at high concentrations (e.g., 30 mg/ml). It was, thus, con-
cluded that the incorporation of triblock copolymer at a
concentration of 30 mg/ml and of lactide at a concentra-
tion of 20 mg/ml (as used in the blend in this study) is safe
and it does not damage cellular growth. Authors suggested
that this 4-component blend made into non-woven scaffold
might be of benefit in cell delivery for bone regeneration.
In a biocompatibility test, Zhong et al.114 used rabbit
conjunctiva fibroblasts to investigate in vitro biocompat-
ibility of blended collagen and either 4% or 10% CS
chondroitin-6-sulfate (CS) n-scaffolds, that were devel-
oped for potential use in tissue engineering. The 4% CS
scaffolds were used as 18% concentration solutions while
the 10% CS ones were used as 12% solutions that under-
went e-spinning. Scaffolds were crosslinked subsequently
by using glutaraldehyde (GA). The 10% CS scaffolds had
lower mean fiber diameter (180 nm), but wider diame-
ter distribution. The 4% CS ones had a mean diameter
of 260 nm. It is worth noting that CS is a salt and
this may have had an effect on conductivity, thus reduc-
ing fiber diameter. Scaffolds were tested for degradation
using collagenase and it was found that cross-linked ones
had significantly lower degradation rate. On day 3, non-
crosslinked scaffolds had 90% of their fibers digested
while crosslinked ones had only 35% digested by 6 days.
Obviously, this was also a factor responsible of increased
cell proliferation that was observed to occur in crosslinked
ones. This also indicates that the used GA did not have
appreciable toxic effects, probably because of the proce-
dure used after cross-linking. In addition, CS 4% scaffolds
were associated with significantly higher cell proliferation
at day 7, when compared to non-CS containing scaffolds.
At day 7, cells exhibited typical fibroblastic morphology
with flattening and polygonal extensions with fibroblast
tethering to the n-fibers. It was concluded that these col-
lagen CS crosslinked scaffolds have excellent biocompati-
bility with potential use in tissue engineering.
Kim et al.139 have used human prostate epithelial cells
to test for cell attachment and proliferation on PCL
n-scaffolds that were developed to have improved wet-
tability by co-electrospinning with PVA. Cell attachment
and proliferation was improved by including PVA which
is probably due to improved scaffold hydrophilicity.
To assess cytocompatibility of silk fibroin with the
aim of developing a nonwoven-type wound dressing, Min
et al.103 used primary human oral keratinocytes, primary
normal human epidermal keratinocytes, and primary nor-
mal human gingival fibroblasts. Silk n-fibers were found
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to promote cell adhesion and spreading of collagen type I.
It was concluded that silk fibroin n-fibers are good candi-
dates for tissue engineering.
3.3.4. In Vivo Studies
An in vivo study (conducted in rats)81 involved non-woven
PCL nanomats that were produced by e-spinning. The
fiber diameter significantly influenced in vivo biodegrada-
tion rates. In vivo degradation was found to be faster than
in vitro. Degradation of nanomats (membranes) was slower
than solvent-cast membranes, probably because they were
more hydrophobic. In another study,140 PCL n-scaffolds
that were seeded with MSCs, were implanted in rats for
4 weeks, and the constructs were found to maintain their
original size and shape.
4. TISSUE ENGINEERING
For tissue engineering, it is important to have a biomimetic
porous structure with thin fibers. In studies on osteoblasts,
it was reported that adhesion, proliferation, alkaline phos-
phatase (AP) activity, and ECM production on carbon
n-fibers was increased with thinner fibers having diame-
ter in the range of 60–200 nm.141 Studying PLLA nano-/
micro-fibrous scaffolds for neural tissue engineering,
Yang et al.13 found that although no significant changes
in neural stem cell orientation were seen with respect to
fiber diameter, the rate of cell differentiation was higher
on PLLA n-fibers than that on microfibers.
Adding molecule release function to nanoscaffolds may
advance applications further for use in controlled tissue
repair. Resulting multifunctional device may enable con-
trol over tissue reactions. Moreover, the use of bioactive
agent releasing n-fibers is a promising tool in tissue engi-
neering where the scaffold can mimic ECM further in
relation to storage and release of morphogens. This can
be employed to promote cell growth, and to modulate
or redirect cell functions,93 making n-scaffolds among
promising native ECM analogs.16
Increasingly, results are being reported on the
use of biodegradable polymeric n-fibers for tissue
engineering37!42!91!136!142 including engineering of neural,13
bone,42!136 cartilage,142 skin,37 and blood vessel30!91!113
tissues. These studies evaluated cell adhesion, prolifera-
tion, gene expression, and ECM secretion. For example,
e-spun EVOH n-fiber mat has also been shown to be able
to support the culture of SMCs and fibroblasts.133 Human
embryonic palatal mesenchymal cells,93 chondrocytes,92
and bone marrow-derived MSCs41 were cultured on PLGA
or PCL n-fibers. The n-fiber structure was found to support
cell attachment and proliferation. NIH 3T3 fibroblasts
tended to maintain their phenotypic shape when they were
cultured on poly(p-dioxanone-co-L-lactide)-block-poly
(ethylene glycol) n-fibers. Growth occurred according to
n-fiber orientation.143
4.1. Cardiovascular Tissues
For potential application in blood vessel tissue engineer-
ing, He et al.113 used collagen-blended P(LLA-CL) 70:30
n-scaffolds and human coronary artery ECs. Enhanced
cell viability, attachment and spreading of cells, and
preservation of EC markers were observed. Enhanced30
endothelialization of collagen-coated structures with good
mechanical properties has also been seen. Human coro-
nary artery SMCs were studied on different types of
matrices (PCL, collagen-coated PCL n-fibers, and col-
lagen n-fibers) to assess suitability for blood vessel
engineering,31 were found to grow in the direction of fiber
orientation. Compared to plain PCL, collagen-coated PCL
fibers were associated with better cell attachment, migra-
tion, and proliferation, as well as better morphology of
%-actin filaments. EC orientation followed aligned n-fibers
(gelatin-grafted PCL n-fibers) with full cell spreading by
days 2 and 4,112 while cells assumed round-shape and
did not spread on random n-fibers. Grafting of gelatin on
PCL has also improved cell proliferation, compared with
the poor cell growth on unmodified PCL. EC phenotype
was also preserved on gelatin-modified PCL, as indicated
by the expression of the important characteristic surface
markers.
Comparing knitting with e-spinning of fibrin gel to
develop materials for blood vessel engineering,32 human
myofibroblasts exhibited good cell proliferation on both
types of scaffolds. Although it was poorer in e-spun ones,
no significant difference in collagen production on both
scaffold types was found. Higher seeding efficiency was
seen in e-spun scaffolds.
Mo et al.130 looked at the cell behaviour of SMCs and
ECs on nanofibrous P(LLA-CL) 75:25 scaffolds. Com-
pared to day 1, there was an increase in cell density of both
cell types at day 3. The cells were also observed to migrate
and proliferate and form a continuous monolayer. At day 7,
cells, especially SMCs, increased significantly in number
and almost reached confluence. Xu et al.33 looked at func-
tion of human vascular ECs on substrates with different
surface roughness (in vitro). They have compared e-spun
PLLA n-scaffolds to solvent cast produced smooth sur-
face films. ECs showed enhanced function on smooth films
as compared to rough surface fibers. In another study,91
human umbilical vein ECs were shown to adhere, spread
and proliferate better on surfaces with high-density fab-
rics and especially on fibers with smaller diameter (0.3
and 1.2 "m). On large-diameter-fiber fabrics (7.0 "m),
cell adhesion was markedly reduced, cell spreading was
restricted and there were no signs of proliferation.91 The
scaffolds with large diameter fibers had also many large-
size pores with cells adhered on single fibers, were round
in shape and with non-proliferating cells predominating.
Such behavior is probably the result of large interfiber dis-
tance or a very low surface density of fibers, which did
not permit cell adhesion across the neighboring fibers.91
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The study, does however, demonstrate potential for appli-
cation of n-scaffolds in vascular tissue engineering. Xu
et al.132 have also looked at human coronary artery SMCs
and ECs on P(LLA-CL) 75:25 e-spun substrates to check
the suitability of such scaffolds for engineering blood ves-
sels. Although both cell types attached and proliferated
well on the scaffolds, the rate was higher for SMCs than
for ECs. However, as time increased, proliferation rate
became slower. Both cell types expressed specific pheno-
types and favorable interactions between SMCs and ECs
on the scaffold were demonstrated.
Stankus et al.34 investigated rat aortic SMCs micro-
integration into poly(ester urethane)urea (PEUU) e-spun
scaffolds. No significant change in SMC number was
seen in static cultures (at 1, 4, and 7 days) while higher
cellular density was seen in perfusion cultures. Improved
physical properties of scaffolds was achieved by the
addition of PLGA to a mixture of collagen type I (from
half skin), elastin (from ligamentum nuchae) and PLGA
(45:40:15).35 Good biocompatibility of the scaffolds
with bovine ECs and SMCs was observed of scaffolds,
making these scaffolds potential candidates for devel-
opment of vascular grafts. n-fiber-based meshes made
by e-spinning of a blend of collagen type I and elastin
in various ratios.134 Fibers had diameters ranging from
220 to 600 nm. Increased elastin content led to increased
fiber diameter. To render them stable, scaffolds were sub-
sequently cross-linked, using N -(3-dimethylaminopropyl)-
N ′-ethylcarbodiimide hydrochloride (EDC), in the
presence of N -hydroxysuccinimide (NHS), to avoid glu-
taraldehyde cytotoxicity.144 SMCs have reached confluence
on the scaffolds by day 14 of culture.
Zong et al.36 investigated the suitability of PLGA
10/90, PLGA 75/25, semi-crystalline PLLA, and PEG-
PDLLA diblock copolymeric e-spun scaffolds for culture
of primary cardiomyocytes and development of engineered
heart tissue. Post-processing was applied to e-spun scaf-
folds to achieve macro-scale fiber orientation (anisotropy).
Fine fiber architecture of the non-woven matrix allowed
cardiomyocytes to crawl inside and pull on fibers.
Cardiomyocytes on e-spun PLLA scaffolds developed
mature contractile machinery (sarcomeres). Functionality
(excitability) of the engineered constructs was also con-
firmed. It was concluded that engineered cardiac tissue
structure and function can be modulated by the chemistry
and geometry of the provided nano- and micro-textured
surfaces.
Li et al.93 studied human embryonic palatal mes-
enchymal cells cultured on collagen, gelatin (denatured
collagen), solubilized %-elastin, and recombinant human
tropoelastin n-scaffolds. On day 2, cell growth on all of
the scaffolds was consistently equal to or (for elastin)
slightly higher than that on the standard tissue culture-
treated polystyrene (TCPS) controls. By day 6, there were
significantly more cells on all the scaffolds than on TCPS.
It was worth noting that cells grew not only on top of
the scaffolds but also into them. Cells that grew at low
densities on the scaffolds were found to elaborate a large
number of pseudopodia, with which they have attached
to individual fibers. Cells attached, spread, migrated, and
proliferated to confluence equally well on collagenous
as on %-elastin and tropoelastin scaffolds. According to
authors,93 these results warrant further investigations on
the use of these matrices, especially the elastin and tropoe-
lastin ones, for engineering, e.g., of cardiovascular and
pulmonary tissues.
4.2. Skin and Mucosal Tissue
Zhang et al.115 reported on the use of human dermal fibro-
blast culture and collagen-coated PCL n-fibers. They have
evaluated two types of such fibers, of which one type was
produced by using coaxial e-spinning to have collagen-
coated individual fibers. The other technique produced
only roughly collagen-coated PCL nanofibrous matrices,
by soaking PCL matrix in collagen. Matrices that had
individual fiber coatings, were associated with definitely
favored cells proliferation. Cell density on these mem-
branes increased almost linearly over 6 days of culture,
but to a lesser extent on roughly collagen-coated PCL.
Individual fiber coating was also associated with encoura-
ged cell migration inside the scaffolds. Although the
primary objective of this study was to compare the two
types of the material and not tissue engineering, gained
results may help to employ this further in tissue engineer-
ing using dermal fibroblasts.
4.3. Neural Tissue
Yang et al.13 explored the efficacy of aligned PLLA
nano/micro e-spun fibrous scaffolds that for neural tis-
sue engineering. Neonatal mouse cerebellum C17.2 stem
cells were cultured with the scaffolds and they were found
to elongate and have neurite outgrowth parallel to the
direction of aligned fibers. No significant relation to fiber
diameter was seen. The rate of cell differentiation was
higher with n-fibers than with microfibers, irrespective of
fiber alignment. Aligned nanofibrous PLLA scaffolds can,
thus, have potential in neural tissue engineering. Scaffolds
developed by Yang et al.38 had an average fiber diameter
of 272 nm, median pore diameter of 21 "m and surface
roughness of 172 nm. Majority of pores had a diameter
of 10 "m, which is sufficient for nutrient exchange, yet
can prevent glial scar formation. This may help to achieve
successful neural tissue regeneration. When cells were cul-
tured on these scaffolds, 61.4% of the cells have adhered
to the scaffolds by 2 h, and 70% differentiated by 1 day as
indicated by exhibiting spindle-like shape with extended
processes. Although cell adhesion was improved on e-spun
PLLA as compared to smooth-surface PLLA films (surface
roughness of 1 nm), PLLA is a hydrophobic material that
does not favour cell attachment. Because cell adhesion is a
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critical step that precedes all other steps of spreading and
differentiation, it was thought that effective physicochem-
ical modification of the surface is necessary to improve
the efficiency of these scaffolds. This scaffold may have
potential in neural tissue engineering.
4.4. Hepatic Tissue
Chua et al.39 found that fibrous poly(#-caprolactone-co-
ethyl ethylene phosphate) scaffolds (average fiber diam-
eter of 760 nm) that were covalently conjugated with
galactose ligands led to better rat hepatocyte aggregate
formation and cell function and scaffold aggregate integra-
tion as compared with scaffolds that had no ligands. Cell
aggregates have embraced n-fibers of the scaffolds. The
study demonstrated that biochemical cues may be more
important than topographical cues in terms of function.
Potentially, these scaffolds may have application in hepatic
tissue engineering.
4.5. Muscle
Riboldi et al.135 have developed e-spun n-scaffolds from
biodegradable DegraPol® (Table I). The scaffolds had a
thickness of about 100 "m, fiber diameter of ca. 10 "m
and a fiber-to-fiber distance of ca. 10 "m with slight
preferential fiber orientation. The scaffolds had a ten-
sile strength of 2.52± 0.17 MPa and elongation at break
of 220.40± 57.9%. Because of the limitations of current
tissue engineering technologies that employ other scaf-
folds, and thus making clinical application unrealistic, this
n-scaffold was developed as a valid alternative. Using
murine myoblast cell line (C2C12), rat myoblast cell line
(L6), and primary human satellite cells (HSCs), were stud-
ied for cell viability, adhesion and differentiation on coated
(with the proteins, Matrigel, fibronectin, or collagen) and
uncoated DegraPol® slides. The study demonstrated the
absence of toxic residuals and satisfactory mechanical
properties. Both cell lines and HSCs adhered, proliferated
and fused on coated scaffolds. C2C12 myotubes tended to
align along the preferential direction of the fibers. Differ-
entiation of C2C12 to multinucleated cells has occurred as
indicated by positive staining for myosin heavy chain.
4.6. Ligament/Tendon
Because a n-fiber matrix alone would not sufficiently
be strong for engineering fibrous connective tissues such
as tendon and ligament, it was thought that a combina-
tion of e-spun n-fibers to knitted scaffold could be more
advantageous. Sahoo et al.98 have thus developed a scaf-
fold that comprised PLGA n-fibers e-spun onto the sur-
faces of a knitted PLGA scaffold, to combine favored
properties (mechanical strength and integrity) of knitted
microfibers to those of n-fibers (large surface area and
the better hydrophilicity), with improved cell attachment,
ECM deposition and tissue formation. Porcine bone mar-
row stromal cells were seeded onto these scaffolds and also
on control knitted PLGA scaffolds. It was found that cell
attachment was comparable in both test groups while cell
proliferation was faster in the new combination scaffold.
Cell function was more active in the combination scaffold
test group as could be indicated by the higher expression
of genes encoding for collagen I, decorin, and biglycan.
4.7. Cartilage
Li et al.41 used human bone marrow-derived MSCs to
assess cell proliferation and mouse fibroblasts to assess
cell interaction with e-spun PLGA scaffolds. The scaf-
folds had a fiber diameter of 500–800 nm, porosity of
91.63% and pore diameter of 2–465 "m (majority 25–
100 "m). Cell numbers in the scaffold increased reaching
a plateau by day 7, and having 5-fold increase by day 10.
Fibroblasts adhered, spread, and migrate under layers of
the scaffold already by day 3 following the direction of
fibers and integrating with them. In addition, the scaf-
fold had good mechanical properties making it suitable
for engineering tissues such as cartilage. Shields et al.102
have developed and investigated collagen type II (from
chicken sternae) n-scaffolds (either cross linked or non-
crosslinked). They have used immortalized cell line of
adult human articular chondrocytes (T/C 28a2) cultures to
look at cell attachment, distribution and proliferation after
7 days in cultures. Average thickness of crosslinked scaf-
folds was 0.52±0.07 mm and that of non-crosslinked ones
was 0.20±0.02 mm. Average fiber diameter in crosslinked
scaffolds was 1.46 "m and that of fibers in non-crosslinked
ones was 496 nm. Non-crosslinked scaffolds had an aver-
age pore area of 6.94 "m2. Non-crosslinked scaffolds had
an average tangent modulus of 172.5±36.1 MPa, ultimate
tensile strength of 3.3± 0.3 MPa, and ultimate strain of
0.026±0.005 mm/mm. Seeded cross-linked scaffolds were
associated with adherence, proliferation, and infiltration
of chondrocytes, including the formation of pseudopo-
dia. Further investigation using additional biochemical and
immunohistochemical methods was suggested for deter-
mining maintenance of the chondrocyte phenotype and the
products of ECM synthesis. It is worth noting that the
thickness of human articular cartilage is approximately
1.5 mm. It is thus important to fabricate thicker e-spun
scaffolds to withstand manipulation for in vivo testing.
e-spun scaffolds can have tailored fiber and pore diam-
eter, fiber orientation, and ultimately specific mechanical
properties, which is an advantage.
Chondrocytic phenotype was evaluated by reverse
transcription-polymerase chain reaction (RT-PCR). Chon-
drocytes seeded on PCL n-scaffolds and cultured in serum-
free medium were found to continuously maintain their
phenotype as indicated by the expression of cartilage-
specific ECM genes. PCL n-fibers were also found to
promote chondrocyte proliferation when serum-containing
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cultures were used.92 Adult bone marrow-derived MSCs
cultured in a PCL n-scaffolds were induced to differentiate
into chondrocytes in the presence of transforming growth
factor $1 (TGF-$1), as indicated by the expression of
chondrocyte-specific genes and the synthesis of cartilage-
associated ECM proteins.93
4.8. Bone
For bone tissue engineering, Tuzlakoglu et al.42 have
shown the potential of starch/PCL (30:70%)-based scaf-
folds. A combination of nano- and micro-fibers, obtained
by e-spinning and fiber bonding techniques, was used as
a 3D scaffold and it has been concluded that this kind of
cell carrier has a higher ability to enhance cell (human
osteoblast-like osteosarcoma SaOs-2 cell line and rat bone
marrow stromal cells) attachment and organization and a
higher AP activity as well, when compared to carriers
without n-fibers.
Yoshimoto et al.43 have seeded PCL n-scaffolds with
neonatal rat bone marrow-derived MSCs. Cell-polymer
dynamic culture contained osteogenic supplements and
was continued for 4 weeks. Cell-polymer constructs main-
tained the size and shape of the original scaffolds. Scaf-
folds were penetrated by cells and abundant ECM was
seen after 1 week in culture. The surfaces of the constructs
were covered with cell multilayers, mineralization and
type I collagen were observed at 4 weeks of culture, sug-
gesting that e-spun PCL is a potential scaffold for engi-
neering of bone.
Li et al.29 studied multifunctional bioactive silk fibroin
fiber scaffolds–based scaffolds. They have combined
these scaffolds either with BMP-2, nanoparticles of
(D) PAM 5% (E) PAM 8% (F) PAM 10%
(A) (B) (C)
Fig. 4. Effect of polymer solution concentration on fiber diameter and bead structure when PHBV-8 polymer was used (A) 5%, (B) 7%, (C) 8%
concentration (w/v). Note that with increasing polymer concentration, fiber diameter increases. Similar observations can also be made with using
PAM14 polymer in concentrations of 5% (D), 8% (E), or 10% (F). Note increasing fiber diameter and reduced number of beads (Original magnification
×5000).
hydroxyapatite (nHAp), or both. They have seeded them
with human bone marrow-derived MSCs, for 31 days in
osteogenic media. It seems that BMP-2 has survived the
aqueous-based e-spinning process and retained its bioac-
tivity, as the scaffolds containing BMP2 were associated
with higher calcium deposition and enhanced transcript
levels of bone-specific markers than in controls. Silk
fibroin scaffolds supported MSC growth and osteogenic
differentiation. Apatite formed on the silk fibroin/BMP-2
scaffolds had higher crystallinity than on the silk fibroin
control scaffolds. nHAp particles were associated with
improved bone formation. Combined BMP-2 and nHAp
silk fibroin scaffolds resulted in the highest calcium depo-
sition and upregulation of BMP-2 making them potential
candidates for engineering of bone tissue engineering and
systems for delivery of labile components.
Fujihara et al.94 developed two types of PCL n-fiber
CaCO3 nanoparticle composite membranes having a PCL
to CaCO3 ratio of either 75:25 or 25:75. They have cul-
tured human osteoblasts on these scaffolds and observed
good cell attachment and proliferation. No significant dif-
ference between the two types of membranes was found.
Authors94 suggested that further studies on osteoblast func-
tions, such as secretion of osteonectin and osteocalcin,
and alkaline phosphatase activity should be conducted
for further understanding of osteoblast behaviors on these
composite n-fiber membranes. The scaffolds have a poten-
tial use in guided bone regeneration.
Badami et al.10 investigated MC3T3-E1 (mouse
calvaria-derived osteoprogenitor cell line) for the effect of
different chemical and topographical features on cell adhe-
sion, morphology, orientation, proliferation, and osteoblas-
tic differentiation. They have used either films (spin-coated
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glass) or e-spun scaffolds of copolymers PDLLA and
PLLA, and block copolymers PEG-PDLLA and PEG-
PLLA (mean fiber diameters 0.14 nm to 2.1 "m). They
have found that proliferation was increased during the
14-days culture period on all types of tested surfaces. In
the absence of osteogenic factors, cell density was less on
fibers than on the smooth surfaces. On the other hand, in
the presence of osteogenic factors cell density on fibers
was equal to or greater than that on smooth surfaces.
In both cases cell density increased with increasing fiber
diameter. There was no detection of ALP in the absence
of osteogenic factors implying that ALP activity was unaf-
fected by fiber topography. However, authors suggested
that future work should involve determining the effects of
fiber diameter on these other phenotypic markers such as
the synthesis of osteocalcin and collagen, and the deposi-
tion of a calcium–phosphate. PCL n-scaffolds seeded with
MSCs and implanted in rats for 4 weeks were found to
be rigid and have a bone-like appearance with cells and
formed ECM were seen throughout the constructs.140
5. FUTURE PROSPECTS
Polymeric nanofiber-based scaffolds have a potential wide
range of potential applications in tissue repair and regen-
eration. Their use in tissue engineering is increasing
rapidly and the potential of a variety of polymers as
scaffold candidates in mimicking the ECM has been
demonstrated. However, employing drug and morphogen
release properties will confer extra properties on multi-
functional scaffolds and mimic further native ECM. Thus,
the convergence of tissue engineering, nanotechnology and
drug release technologies is expected to address more of
current challenges in the success and functionality of engi-
neered grafts for regenerative medicine. To realize this, a
multidisciplinary approach is needed and the development
of new processing methods is essential. With appropriate
funds, advances made by such convergence of research
fields will have impact on science, therapy, industry, and
ultimately economy.
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